Search
Tertomotide
go.drugbank.com/drugs/DB12747InvestigationalTertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma). … It is a peptide vaccine that activates the immune system so that it recognizes and kills cancer cells. It is being developed by Pharmexa A/S.
Regramostim
go.drugbank.com/drugs/DB05386InvestigationalEndothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. … Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages.
Synonyms: Colony-stimulating factor 2 (human clone pCSF-1 protein moiety reduced), glycoform GMC 89-107TAFA-93
go.drugbank.com/drugs/DB05887ExperimentalTAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation … , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease.
ISIS 113715
go.drugbank.com/drugs/DB05506InvestigationalIn early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol. … ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes.
MD05
go.drugbank.com/drugs/DB06375InvestigationalMD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).
Brolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigational[L9089] Brolucizumab was granted FDA approval in October 2019.[L9089] … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Products: VSIQQ® SOLUCION INYECTABLE, Xivubel 120 mg/ml Enjeksiyonluk Çözelti, 1 adetPYM50018
go.drugbank.com/drugs/DB05126ExperimentalPYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.
Metacycline
go.drugbank.com/drugs/DB00931ApprovedA broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.
Synonyms: 6-Demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline, 6-Deoxy-6-demethyl-6-methylene-5-oxytetracyclineContusugene ladenovec
go.drugbank.com/drugs/DB05322InvestigationalINGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. … Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.
Motexafin lutetium
go.drugbank.com/drugs/DB05296InvestigationalMotexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties. … Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More Rings